Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
Theriva Biologics (NYSE American: TOVX), a clinical-stage company focused on developing cancer therapeutics in areas of high unmet need, has announced its participation in the upcoming Q1 Investor Summit Virtual.
The company's presentation will feature CEO Steve Shallcross and General Director Dr. Manel Cascallo, scheduled for Tuesday, March 11, 2025, at 12:30 PM ET. The management team will also engage in one-on-one meetings during the event.
Theriva Biologics (NYSE American: TOVX), un'azienda in fase clinica focalizzata sullo sviluppo di terapie contro il cancro in aree di alto bisogno non soddisfatto, ha annunciato la sua partecipazione al prossimo Q1 Investor Summit Virtual.
La presentazione dell'azienda vedrà la partecipazione del CEO Steve Shallcross e del Direttore Generale Dr. Manel Cascallo, programmata per martedì 11 marzo 2025, alle 12:30 PM ET. Il team di gestione parteciperà anche a incontri individuali durante l'evento.
Theriva Biologics (NYSE American: TOVX), una empresa en etapa clínica centrada en el desarrollo de terapias contra el cáncer en áreas de alta necesidad no satisfecha, ha anunciado su participación en el próximo Q1 Investor Summit Virtual.
La presentación de la empresa contará con la participación del CEO Steve Shallcross y del Director General Dr. Manel Cascallo, programada para el martes 11 de marzo de 2025, a las 12:30 PM ET. El equipo de gestión también participará en reuniones individuales durante el evento.
Theriva Biologics (NYSE American: TOVX), 높은 미충족 수요 영역의 암 치료제를 개발하는 임상 단계 회사가 다가오는 Q1 투자 서밋 가상 행사에 참여한다고 발표했습니다.
회사의 발표에는 CEO Steve Shallcross와 총괄 이사 Dr. Manel Cascallo가 포함되며, 2025년 3월 11일 화요일 오후 12시 30분 ET에 예정되어 있습니다. 경영진 팀은 행사 동안 일대일 미팅에도 참여할 예정입니다.
Theriva Biologics (NYSE American: TOVX), une entreprise en phase clinique axée sur le développement de thérapies contre le cancer dans des domaines de forte nécessité non satisfaite, a annoncé sa participation au prochain Q1 Investor Summit Virtuel.
La présentation de l'entreprise mettra en vedette le PDG Steve Shallcross et le Directeur Général Dr. Manel Cascallo, prévue pour mardi 11 mars 2025, à 12h30 ET. L'équipe de direction participera également à des réunions individuelles pendant l'événement.
Theriva Biologics (NYSE American: TOVX), ein klinisches Unternehmen, das sich auf die Entwicklung von Krebstherapien in Bereichen mit hohem ungedecktem Bedarf konzentriert, hat seine Teilnahme am kommenden Q1 Investor Summit Virtual bekannt gegeben.
Die Präsentation des Unternehmens wird CEO Steve Shallcross und Generaldirektor Dr. Manel Cascallo umfassen, die für Dienstag, den 11. März 2025, um 12:30 Uhr ET angesetzt ist. Das Managementteam wird außerdem während der Veranstaltung an Einzelgesprächen teilnehmen.
- None.
- None.
ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva’s management team will participate in 1x1 meetings.
Q1 Investor Summit Virtual
Format: Presentation
Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director
Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET
Webcast: Click Here
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
For further information, please contact:
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
When is Theriva Biologics (TOVX) presenting at the Q1 Investor Summit Virtual?
Who will represent TOVX at the Q1 Investor Summit Virtual presentation?
What type of meetings will TOVX management participate in during the Q1 Investor Summit?
What is the main focus of Theriva Biologics' (TOVX) therapeutic development?
